16:09 EST Cartesian Therapeutics (RNAC) files $400M mixed securities shelf
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics price target raised to $45 from $41 at H.C. Wainwright
- Cartesian Therapeutics Reports Promising Phase 2b Trial Results
- Cartesian Therapeutics reports positive updated Phase 2b results in myasthenia
- Needham biotech analyst holds an analyst/industry conference call
- Cartesian to present updated data from Phase 2b trial of Descartes-08